Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2019—ChromaCode announced publication of a study by the Medical College of Wisconsin, Milwaukee, and Gundersen Medical Foundation, La Crosse, Wis., highlighting the performance and utility of the High-Definition PCR Tick-Borne Pathogen Panel RUO.
November 2019—Alcor Scientific introduced the miniiSED, the newest addition to its iSED family of erythrocyte sedimentation rate analyzers.
November 2019—A study conducted by Medical Database (Leblow L, et al. J Clin Lab Med. Sept. 5, 2019. doi:10.16966/2572-9578.128) showed that its laboratory decision system, LDS, reduced unnecessary test ordering.
November 2019—The U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease. The tests cleared involve a new testing paradigm in which two enzyme immunoassays are run concurrently or sequentially, rather than the current two-step process in which a Western blot must be run after the initial EIA test.
November 2019—Binding Site’s Immunologicals Group has expanded its line of antibodies and antigens for human coagulation testing applications. Prothrombin and glycerol-free prothrombin proteins are available as antigens, and antibody products include anti-human factor H, factor I, fibrinogen, fibronectin, plasminogen, prothrombin, thrombin, and von Willebrand factor.
November 2019—Thermo Scientific’s Sensititre Gram Negative MDRGN1F AST Plate is now available on the Sensititre AST System. This format offers eravacycline, omadacycline, and plazomicin on an FDA-cleared, IVD-labeled microbroth dilution susceptibility plate for antimicrobial susceptibility testing using second-line multidrug-resistant organism therapies with expanded dilution ranges for Gram-negative organisms.
Biocare Medical released a mouse monoclonal antibody, p16 INK4a, for in vitro diagnostic use in the qualitative identification of the p16 INK4a protein by immunohistochemistry in formalin-fixed, paraffin-embedded human tissues.
November 2019—Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBeam RAS CRC Kit, used for blood-based circulating tumor DNA molecular testing of mutations in the RAS gene for advanced colorectal cancer patients.
November 2019—The Centers for Medicare and Medicaid Services granted approval for a new technology add-on payment (NTAP) to T2 Biosystems’ T2Bacteria Panel, for fiscal year 2020. The T2Bacteria Panel is the first in vitro diagnostic test to receive approval for NTAP, according to the company.
November 2019—MicroMedicine introduced Sorterra, an automated, microfluidics-based cell isolation and concentration system for research and development and clinical research labs. Sorterra isolates white blood cells from 3 to 75 mL of anticoagulated peripheral blood at a rate of 150 mL per hour.
